Cold email campaign for biotech & clinical data — 1% response rate

LinkedIn connection request Date sent: first day of the sequence Sender: {{salesRep}} Content: --- → Invitation to connect on LinkedIn: (Leave this field blank to bypass LinkedIn’s limit of 5 personalised invitations per day and send 20 invitations per day) --- → Introduction (sent 1 day after the LinkedIn connection request is accepted): Hello {{firstName}}, lovely to connect with you. I emailed you at {{email}} regarding the recent challenges biotech teams face when collaborating on real-world data. Did you receive my email? You and I both know that access to clinical information is crucial to avoid slowing down progress. Is this something that poses a problem at {{companyName}}, or not at all? --- → Message mentioning colleagues’ names (sent 5 days later): {{firstName}}, would it be better to discuss real-world data with {% if colleaguename1 != blank and colleaguename2 != blank %}{{colleaguename1}} or {{colleaguename2}}{% elsif colleaguename1 != blank %}{{colleaguename1}}{% elsif colleaguename2 != blank %}{{colleaguename2}}{% else %}a member of your R&D or clinical development team{% endif %} ? I’m curious to know how {{companyName}} utilises clinical data from hospitals nationwide to facilitate feasibility studies and reduce time-to-market (rather than waiting months for access authorisations and missing out on necessary data sources) --- → Message mentioning colleagues’ names (sent immediately afterwards): *data from clinical practice, sorry --- → Distancing message (sent 7 days later): Dear {{firstName}}, Could we get back in touch in a few months, once the clinical data from {{ region}} has become more significant at {{companyName}}? Have a good day

Version A – abridged version with icebreaker activity Dear {{firstName}}, {{icebreaker}} You know how difficult it is to access sensitive health data securely and in compliance with European privacy regulations. Every day, this slows down decision-making, causes delays and prevents access to valuable, actionable information. Roche and DebioPharm have chosen our federated solution to transform their oncology research as part of the NAIPO project. Would you like to receive a brief document explaining how this solution supports their team? Kind regards, {{signature}} unsubscribe Version B – shorter version without introduction Dear {{firstName}}, You know how difficult it is to access sensitive health data securely and in compliance with European privacy regulations. Every day, this slows down decision-making, causes delays and prevents access to valuable real-world information. Roche and DebioPharm have chosen our federated solution to transform their oncology research as part of the NAIPO project. Would you like to receive a short document explaining how this solution supports their team? Kind regards, {{signature}} unsubscribe

Hello {{firstName}}, Should I contact {% if Colleaguename1 != blank and Colleaguename2 != blank %} your colleagues {{Colleaguename1}} or {{Colleaguename2}}, your colleague {% elsif Colleaguename1 != blank %}, your colleague {{Colleaguename1}}, your colleague {% elsif Colleaguename2 != blank %}, or another member of your team {% endif %}? We would be delighted to show you and your colleagues how {{companyName}} could also benefit from similar collaborations involving real-world data. Six major Swiss university hospitals have set up a federated network linking more than 600,000 patient records. They carry out cross-site queries in a matter of minutes and design studies based on larger and more diverse patient groups, all in full compliance. Have a great day! PS: My to-do list below reminded me to write to you 😊 {{accountSignature}} Unsubscribe

Hello {{firstName}}, Here is the link to the short case study I mentioned to you, which explains how {{testimony company}} is transforming oncology research using AI as part of the NAIPO project in Switzerland. I thought you might be interested to see how: 1/AI models work on federated real-world clinical datasets 2/data security is not compromised 3/compliance is simplified between partners Is this a topic that interests you, or not at all? Kind regards, {{signature}} unsubscribe

Hello {{firstName}}, This might not be the ideal time to discuss how data from clinical practice can support your research. May I get back to you in about three months to see if your priorities have changed? P.S.: In the meantime, here’s a virtual coffee for you to enjoy whilst we wait for our next meeting ☕️ {{accountSignature}} Unsubscribe